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Abstract
Background and Objective: To identify and characterize subgroups of adolescents with type 1 
diabetes (T1D) and elevated hemoglobin A1c (HbA1c) who share patterns in their continuous 
glucose monitoring (CGM) data as ‘dysglycemia phenotypes.’
Methods: Data were analyzed from the Flexible Lifestyles Empowering Change randomized 
trial. Adolescents with T1D (13-16 years, duration>1 year, HbA1c 8-13% (64-119 mmol/mol) 
wore blinded CGM at baseline for 7-days. Participants were clustered based on eight CGM 
metrics measuring hypoglycemia, hyperglycemia, and glycemic variability. Clusters were 
characterized by their baseline features and 18-month changes in HbA1c using adjusted mixed 
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effects models. For comparison, participants were stratified by baseline HbA1c (≤/>9.0% (75 
mmol/mol)).
Results: The study sample included 234 adolescents (49.8% female, age 14.8±1.1, duration 
6.4±3.7 years, HbA1c 9.6±1.2% (81±13 mmol/mol)). Three Dysglycemia Clusters were identified 
with significant differences across all CGM metrics (p<0.001). Dysglycemia Cluster 3 (n=40, 
17.1%) showed severe hypoglycemia and glycemic variability with moderate hyperglycemia and 
had a lower baseline HbA1c than Clusters 1 and 2 (p<0.001). This cluster showed increases in 
HbA1c over 18-mo (p-for-interaction=0.006). No other baseline characteristics were associated 
with Dysglycemia Clusters. High HbA1c was associated with lower pump use, greater insulin 
doses, more frequent blood glucose monitoring, lower motivation, and lower adherence to diabetes 
self-management (all p<0.05).
Conclusions: There are subgroups of adolescents with T1D for which glycemic control is 
challenged by different aspects of dysglycemia. Enhanced understanding of demographic, 
behavioral, and clinical characteristics that contribute to CGM-derived dysglycemia phenotypes 
may reveal strategies to improve treatment.
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Introduction
While hemoglobin A1c (HbA1c) is the gold standard for measuring intermediate-term 
glycemic control, continuous glucose monitoring (CGM) data captures transient glucose 
fluctuations to various thresholds of hypoglycemia and hyperglycemia, as well as overall 
glycemic variability in the daytime and overnight.1,2 These features of dysglycemia 
represent distinct clinical issues for individuals with type 1 diabetes which may be amenable 
to different self-management and medication adjustments.1 They also confer independent 
risk for short and long-term complications of type 1 diabetes.1-4 Recently, CGM data have 
also been used to provide validated metrics such as time in range5,6 or average glucose 
exposure over a shorter period of time, also referred to as the Glucose Management 
Indicator.7 CGM as a source of patient data thus offers the opportunity to understand 
patterns of glycemia that are not necessarily represented by HbA1c and inform an 
individualized approach to type 1 diabetes management for decreased patient burden and 
better outcomes.1
The most effective strategy to both leverage the depth and integrate the breath of information 
that CGM offers remains unclear, especially in light of the rapidly increasing uptake of 
CGM.8 This step is critical to inform tailored approaches to diabetes care. We focused on 
young individuals with type 1 diabetes and suboptimal glycemic control as it is measured by 
HbA1c because this population is in great need for improved clinical strategies.8,9 Our 
objective was to use longitudinal CGM data from adolescents with type 1 diabetes and 
elevated HbA1c >65 mmol/mol (8.0%) to identify clinically-relevant subgroups sharing 
multifacteted patterns in hypoglycemia, hyperglycemia, and glycemic variability as distinct 
‘dysglycemia phenotypes’. These comprehensive dysglycemia phenotypes could be used to 
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characterize glycemic control across the population in a more nuanced, patient-oriented 
manner compared to HbA1c and inform the development of future interventions.2
To follow best practices and maximize relevance to future research, we used a combination 
of CGM metrics consistent with Advanced Technologies & Treatments for Diabetes (ATTD) 
Congress consensus statement to standardize the reporting of CGM variables in clinical and 
epidemiologic research.10 Given significant skews in the distribution of key CGM metrics 
across the sample that are important to clinical care, namely hypo- and hyperglycemia, it 
was important to identify a statistical method that would retain information from data at the 
extremes of the distribution. We chose a neural-network approach to clustering and grouped 
individuals based on their placement on a self-organzing map (SOM) constructed from eight 
CGM metrics selected to be maximally clinically-relevant.11 The SOM is a machine 
learning technique that is robust to different distributions of data when uncovering 
underlying clusters.12 We then tested for differences in the baseline sociodemographic, 




Data were analyzed from the baseline visit of the Flexible Lifestyles Empowering Change 
randomized trial (FLEX) (ClinicalTrials.gov identifier: NCT01286350). FLEX was a 
randomized clinical trial testing an adaptive, 18-month intervention including behavioral 
skills and problem solving for youth with type 1 diabetes, with respect to HbA1c (primary 
outcome), glycemic variability, CVD risk factors, health-related quality of life, and cost 
effectiveness.13 The study was conducted at two pediatric endocrinology diabetes clinics in 
Colorado and Ohio, USA, with institutional review board approval for ethical conduct of 
human subjects research at each institution and at the coordinating center located in North 
Carolina.
Inclusion Criteria
FLEX enrolled 258 adolescents with type 1 diabetes who were instructed to wear a blinded 
CGM for 7 days at baseline.14 Participants were recruited from 05/0½014 to 04/04/2016.14 
Eligible participants were youth ages 13-16 years with type 1 diabetes for ≥1 year, literacy 
in English, HbA1c 64-119 mmol/mol (8.0-13.0%), and ≥1 primary caregiver with no other 
serious medical conditions or pregnancy. All participants and their caregivers provided 
informed assent and consent, respectively. Detailed considerations of the FLEX design and 
baseline participant characteristics have been described elsewhere.14
Participants were excluded from the present analyses if they reported a severe hypoglycemic 
event (an episode of hypoglycemia requiring external aid) during the study week (n=0) or if 
≥24 hours of CGM data were missing at the baseline visit (n=24).
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All data collection was standardized as per FLEX study protocol and are described in detail 
elsewhere.14
Continuous Glucose Monitoring—A blinded CGM [iPro®2 Professional CGM; 
Medtronic Diabetes, Northridge, CA; median absolute relative difference: 11.1%] was worn 
for a 7-day period to measure interstitial glucose levels in real time throughout the day and 
night. At the baseline visit, study participants inserted the iPro®2 CGM system with the 
Enlite™ sensor into abdominal subcutaneous adipose tissue. Participants were carefully 
instructed on the use and maintenance of the CGM and advised to calibrate the sensor before 
eating and before bed with an iPro2 compatible glucometer (OneTouch® Ultra® 2). The 
Enlite™ sensor measured interstitial glucose level every 5 minutes within the 3-147 
mmol/mol (40-400 mg/dL) range. On the last day of the CGM wear week, participants were 
reminded to send the devices back using a pre-paid box/envelope. CGM data were 
downloaded with CareLink iPro® System and uploaded to the coordinating center for data 
processing. As part of blinding, no communication from the device was available to 
participants.
Laboratory data—A central laboratory (Northwest Lipid Metabolism and Diabetes 
Research Laboratories, Seattle, WA, USA) provided oversight and conducted all assays. At 
all timepoints, HbA1c was measured in whole blood using an automated nonporous ion 
exchange HPLC system (model G-7; Tosoh Bioscience).
Clinical Measures—Height was measured using a stadiometer, and weight was measured 
to the nearest 0.1 kg using an electronic scale. Body mass index (BMI, weight (kg) / height 
(m)2) was calculated and then converted to an age- and sex-specific and BMI z-score (BMIz) 
according to the Centers for Disease Control and Prevention growth charts.15
Questionnaires—Standardized questionnaires were used to collect self-reported data 
including race/ethnicity, highest level of parental education, duration of type 1 diabetes, 
insulin delivery method (pump versus multiple daily injections (MDI)), and previous CGM 
use. Self-reported race and ethnicity was classified as non-Hispanic white, non-Hispanic 
Black, Black, and other including Asian/Pacific Islander, Native American, or unknown. 
Motivation and Intention were measured by a validated questionnaire adapted for relevance 
to type 1 diabetes self-management.16,17 The Social Problem Solving Inventory – Revised: 
Short (SPSI-R:S) was used to assess adolescents’ cognitive, affective, and behavioral 
abilities to resolve problems in everyday living.18 Diabetes adherence over the past 3 months 
was measured with the Diabetes Self-Management Profile – Self Report (DSMP-SR).19. 
Depressive symptoms were assessed using the Centers for Epidemiologic Study – 
Depression Scale (CES-D).20 Health-related quality of life was assessed with the Pediatric 
Quality of Life Inventory™ – Generic Core Scales (PedsQL™ Generic).21 Fear of 
hypoglycemia was assessed by the Hypoglycemia Fear Survey (HFS) 22. Adolescent-
reported diabetes-related family conflict was measured with the Diabetes Family Conflict 
Scale (DFCS).23
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CGM Data Selection of Variables and Pre-processing—All CGM-variables were 
calculated for the 7-day wear time and were stratified by day (6:00 AM – 11:59 PM) and 
night (12:00 AM – 5:59 AM).10 First, a subset of eight CGM features recommended by the 
ATTD Congress as key metrics to assess glycemic control, reported by day and night, were 
selected for a total of sixteen variables (see Supplementary Material; Section 1).10 The 
justification for using CGM measures stratified by time block was two-fold. First, from a 
clinical and behavioral perspective, patterns in dysglycemia in the daytime versus overnight 
represent distinct phenomena and may carry specific implications for future intervention. 
For example, frequent hypoglycemia overnight is a distinct clinical issue from frequent 
hypoglycemia during the daytime, particularly in the youth and adolescent age range, and 
may be associated with different risk factors. In addition, CGM metrics by day and night 
were not found to be highly colinear from a statistical perspective. The variables were 
pruned to remove highly correlated variables, biological redundancy, and degrees of freedom 
(Supplementary Figure S1).24 The remaining eight CGM input metrics were selected to 
comprehensively characterize features of dysglycemia in the day and nighttime: area-over-
curve (AOC) of hypoglycemia (level 1; 3.9 mmol/L (70 mg/dL)), incidence of hypoglycemia 
(level 1; 3.9 mmol/L (70 mg/dL)) lasting 15 minutes or longer, area-under-curve (AUC) of 
hyperglycemia range (level 2; 13.9 mmol/L (250 mg/dL)), and glycemic variability as 
coefficient of variation (CV) (Supplementary Table S1). Of note, time in range was not 
included due to multicollinearity with the AUC 250 mg/dL metric (r= −0.80, p<0.0001). All 
variables were left continuous and standardized to be expressed on the same scale. To 
facilitate clinical interpretation, clusters were also characterized by percent of time spent in 
hypoglycemic (<3.9 mmol/L (70 mg/dL)) and hyperglycemic (13.9 mmol/L (250 mg/dL)) 
ranges, using the same threshold as the AOC and AUC measures, as well as time in range 
(3.9-10 mmol/L (70-180 mg/dL)).
Clustering Methods—The selection of SOM as a clustering algorithm and an in-depth 
description of the methods are deferred to the Supplementary Material; Section 2. Briefly, 
the SOM is a neural network11 that serves as a model-based clustering method 
(Supplementary Figure S2).24,25 The a priori justification for selecting a neural network-
based clustering approach was that it does not rely on strong assumptions about the 
underlying data such as the distributional assumption of multivariate normality or symmetry.
12 For measures of hypoglycemia and hyperglycemia, some individuals never experienced 
time below or above the threshold, resulting in severely skewed distributions resistant to 
transformation. The ability of the SOM to accommodate skewed input data12 and capture 
information in the tails of the distribution was considered critical to understanding the range 
of dysglycemia in the sample. Finally, SOMs have strong visualization attributes to 
understanding complex, multivariate relationships and improve the validity of unsupervised 
learning.25,26
FLEX participants were mapped based on their eight CGM measures to a 5×5 square grid 
SOM with a Gaussian neighborhood function using the Package ‘SOMBrero’ in R version 
3.4.2.27 The dimensions of the SOM were selected based on the total sample size 24. 1000 
iterations (approximately 4.3 cycles through the full data) were run to ensure the shape of 
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the grid stabilized. Input data was randomized to produce a more reliable neighborhood 
structure. Additional analyses observed stability of the map across testing and training 
partitions. The final map was run on the full dataset to maximize statistical power.
The SOM was randomly initialized and re-run 10 times on the full data to check for 
consistency in parameters and quality criteria (see Supplementary Table S2). The best out of 
10 maps were selected based on the lowest quantization error, a measure of the average 
Euclidian distance between a participant’s CGM measures and the codebook vector of their 
assigned unit (Supplementary Material; Section 3). A hierarchical clustering algorithm was 
applied to the codebook vectors of the final map units using the function superclass in the 
SOMbrero package.28 The NbClust package in R guided the selection of the final number of 
clusters, with minimum and maximum number of clusters set to 1 and 10, respectively.29 
Clusters from the SOM were validated for internal validity, stability, and fidelity to the 
original data (Supplementary Material; Section 4.)
Baseline Characterization and Associations with Longitudinal Clinical 
Outcomes—The baseline correlates of each cluster were summarized using descriptive 
statistics. Skewed variables were assessed using non-parametric tests. Overall-tests of 
difference were carried out using ANOVA and chi-squared tests or Kruskal-Wallis and 
Fisher’s exact tests, where appropriate. Pairwise comparisons were performed via unpaired 
t-tests or Dunn’s test. To discern the significance of Dysglycemia Clusters versus subgroups 
defined by HbA1c, FLEX participants were also stratified by baseline HbA1c: (≤ or >75 
mmol/mol (8.0%)) and described in terms of their baseline characteristics. Significance 
differences across baseline HbA1c groups were tested using chi-squared tests and unpaired 
t-tests.
Mixed effect regression analysis was used to determine whether observed dysglycemia 
clusters show differential changes in HbA1c over 18-months. A main effect was fit for visit 
and cluster and a visit*cluster interaction term. Participants were treated as random effects to 
take into account the repeated measures. All models were adjusted for randomization status 
and site. Post-hoc comparisons by cluster were performed within each mixed model analysis 
and the effects were examined at each longitudinal timepoint in the FLEX study. Descriptive 
statistics and multilevel modeling (PROC MIXED) were conducted in SAS 9.4 (SAS 
Institute, Cary, NC).
Additional Statistical Considerations—SOM has been used previously to cluster 
small datasets, outperforming k-means on data of similar dimensions to the FLEX data 30. P-
values were evaluated at the 0.05 significance level and were not adjusted for multiple 
comparisons in the exploratory analysis.
Results
The final study sample included 234 adolescents with type 1 diabetes. Participants were 
76.1% non-Hispanic white and 50.0% female with mean age 14.8±1.1 years and mean 
diabetes duration was 6.4±3.7 years (Table 1). Mean HbA1c was 81±13 mmol/mol 
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(9.6±1.2%). Participants had blood glucose readings for a median of 160.0 hours (IQR 24.8) 
or approximately 6.7 days.
Figure 1A visualizes the 5×5 SOM grid, where individuals with similar CGM measures are 
assigned to proximal map units. Further visualizations are available in Supplementary Figure 
S3. Three clusters were identified, capturing areas of the map that were similar to each other 
with regards to the 8 CGM metrics (Figure 1B). All CGM metrics showed significantly 
different means and medians across clusters (p<0.001) (Table 2, Figure 1C). Cluster 1 
comprised 141 individuals (60.3%) and showed severe daytime hyperglycemia with low 
exposure to and incidence of hypoglycemia relative to other clusters. Cluster 1 also showed 
the lowest glycemic variability (mean (SD) daytime and nightime CV: 35.5% (6.4%) and 
35.7% (10.7%), respectively). Cluster 2 comprised 53 indiviudals (22.7%) and showed 
severe hyperglycemia, particularly overnight, with moderate hypoglycemia (median (IQR) 
daytime episodes: 4 (3)) and moderate variablity. Cluster 3 comprised 40 individuals 
(17.1%) and showed moderate hyperglycemia with the highest measures of hypoglycemia 
exposure and incidence relative to the other clusters (median (IQR) daytime episodes over 
the 7 days: 8 (5.5)). This group also showed the highest glycemic variability in the daytime 
and overnight (mean daytime and nightime CV: 4.1% (7.0%) and 51.7% (12.9%), 
respectively).
Mean baseline HbA1c was highest in Cluster 1 (85±14 mmol/mol (9.9±1.1%)) and lowest in 
Cluster 3 (72±9 mmol/mol (8.7%±0.8%)). In pairwise comparisons, Cluster 3 showed 
significant differences from Clusters 1 and 2 (p<0.001), but Clusters 1 and 2 did not show 
significant differences from each other (p=0.07). No other baseline characteristics were 
significantly different across clusters. There were differences in the correlates of subgroups 
defined by baseline HbA1c. Compared to participants with HbA1c ≤ 75 mmol/mol (9.0%) at 
baseline, participants with a high HbA1c showed lower insulin pump use (p=0.2), greater 
insulin doses (p=0.03), a higher frequency of blood glucose monitoring (p=0.004), lower 
motivation (p=0.03), and adherence to diabetes self-management (p=0.003).
HbA1c measures over 18-months were significantly different across clusters, adjusted for 
study site and randomization (p-for-interaction=0.006; Figure 2, Supplementary Table S5). 
Dysglycemia Clusters 1 and 2 showed stable mean HbA1c, while Dysglycemia Cluster 3 
showed significant increases over the 18-month study period (mean baseline HbA1c: 71 
mmol/mol (8.7%); mean HbA1c at 18-month visit: 81 mmol/mol (9.6%). There were no 
signifiant differences in mean HbA1c level at the 18-month visit (p=0.71). CGM metrics at 
the 18-month visit for each cluster are depicted in Supplementary Table S6.
Discussion
Using 7-day blinded CGM data from 234 adolescents with type 1 diabetes and elevated 
HbA1c, we identified three distinct, clinically-meaningful clusters sharing phenotypes 
defined by different exposure to and incidence of hypoglycemia, exposure to hyperglycemia, 
and glycemic variability. All eight CGM metrics were significantly different across clusters 
and can thus considered to be relevant for the clustering definition. Subgroups showed 
differences in baseline and longitudinal HbA1c. However, there were no other significant 
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differences in baseline characteristics according to dysglycemia cluster. These results 
reinforce the concept that adolescents with type 1 diabetes and elevated HbA1c do not show 
homogenous patterns in CGM-measures of blood glucose dynamics; this analytic approach 
can help refine understanding of dysglycemia patterns to better identify interventions. 
Interestingly, different patterns in dysglycemia are not explained by the individual 
sociodemographic, clinical, or psychosocial characteristics that typically drive treatment 
recommendations with regards to HbA1c.
To our knowledge, there is limited data available for comparison because the majority of 
existing CGM data collected in comparable age ranges are from adolescents with lower 
HbA1c levels.31 Patterns in dysglycemia across clusters are consistent with other CGM 
studies suggesting that a positive association between glycemic variability and the risk for 
hypoglycemia.32
A previous cluster analysis using 3-days of data from self-monitoring blood glucose values 
provided evidence for distinct glycemic profiles among a small sample of adults with type 1 
diabetes.33 Although all FLEX participants had elevated HbA1c as per inclusion criteria, we 
found similar evidence for the existence of subgroups typified by specific blood glucose 
dynamics. The striking differences in CGM measures suggest that these distinct 
‘phenotypes’ are comprised of adolescents who struggle with different aspects of their blood 
glucose control. For example, individuals in Cluster 1 were typified by hyperglycemia with 
fewer episodes of hypoglycemia and less pronounced variability, especially overnight, while 
individuals in Cluster 3 experienced less hyperglycemia but a median of 8 episodes of 
hypoglycemia per week with severe variability in the daytime and nighttime (mean CV: 47% 
and 52%, respectively). Measures of variability in the latter group greatly exceeded the CV 
threshold of 36% that has previously been proposed to indicate ‘unstable’ glycemia and 
increased risk for hypoglycemia.32
In the analysis to identify potential patient-related drivers of the clusters, there were no 
significant differences in the sociodemographic, clinical, or psychosocial measures across 
Dysglycemia Clusters. One possible reason for the lack of statistically significant correlates 
is the small sample size which may limit statistical power. We explored the clinical utility of 
a 2-cluster solution to detect differences but failed to identify significant correlates to 
distinguish the two subgroups (Supplementary Material, Section 6, Tables S7-S9).
Another interpretation of the data is that a broad range of demographic, clinical, or 
psychosocial characteristics do not drive the specific blood glucose issues that may be 
challenging overall glycemic control among adolescents with type 1 diabetes and elevated 
HbA1c. It is particularly interesting that the risk factors of poor glycemic control as it is 
measured by HbA1c do not appear to be risk factors for poor glycemic control as it 
manifests as membership in a Dysglycemia Cluster. Within the FLEX sample, participants 
with a high baseline HbA1c showed lower insulin pump use, greater insulin doses, a higher 
frequency of blood glucose monitoring, and lower motivation and adherence to diabetes self-
management; none of these associations emerged as correlates of Cluster membership. Other 
well-studied associations of suboptimal HbA1c measures in this age range were not 
replicated as differences across subgroups, including nonwhite race,34 lower measures of 
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socioeconomic position,35 and poorer psychosocial well-being.35 More work is needed to 
understand the drivers of dysglycemia phenotypes, including significant behavioral 
mediators or patterns that can be addressed clinically such as omitted or ill-timed boluses 
with regards to meal initiation.
There are several points of clinical relevance for the findings. Because the extraction of key 
clinical metrics from longitudinal CGM data emulates the process of patient care where 
these measures are used to identify specific issues,2 this study offers proof-of-principle for 
how CGM data may be consolidated and used to identify the subgroups of patients within a 
specific population of individuals with T1D that are be recognizable to care providers as 
intuitive clinical phenotypes. Such subgroup identification compliments the use of CGM 
data in individuals to measure time in range5,6 or average glucose exposure over a shorter 
period of time.7 CGM-derived subgroups may also act as prognostic phenotypes with 
different longitudinal trends in key clinical outcomes such as HbA1c. With increasing 
availability of CGM data as well as documentation of treatment regime and other outcomes 
in electronic health records, this work may in the future offer an emerging platform to pool 
data across one or more clinics to test how CGM clusters function as predictive or 
prescriptive phenotypes for treatment recommendations.
Outside of the clinic, the results may be used towards the development of effective 
interventions for this at-risk and challenging adolescent population.8,13 Although main 
analysis of the FLEX intervention did not show improvements in HbA1c at 18-months,13 a 
three-way interaction term between cluster, FLEX intervention randomization assignment, 
and timepoint was tested in exploratory longitudinal analyses; it was not statistically 
significant. It is possible that approaches to diabetes management in the heterogenous 
adolescent population are maximally effective as a set of interventions tailored to specific 
issues of dysglycemia, which can then be targeted towards phenotypes that are expected to 
maximally benefit. For example, Cluster 3 was the only subgroup to show an increase in 
HbA1c over 18-months; this subgroup also had the highest hypoglycemia and variability at 
baseline and may represent a previously-proposed sequela of recurrent hypoglycemia and 
overcorrection that leads to worsened glycemic control over time.36 Therefore, this group 
may benefit from specific efforts addressing frequent hypoglycemia and its overcorrection 
early in adolescence. By contrast, interventions focused on increasing insulin doses may be 
salient for Cluster 1, who spends most of the time in hyperglycemic ranges with low 
variability, rendering hypoglycemia counseling less immediately relevant.
A further aspect of clinical significance is the presumed differential risk for acute and 
chronic diabetes complications across clusters. Aside from well-established risk associated 
with hyperglycemia,9 the high degree of glycemic variability noted in Clusters 2 and 3 may 
confer additional, independent risk for micro- and macrovascular complications, including 
cardiovascular disease.3,4 Cluster 3’s pattern of hypoglycemia may contribute to the 
development of defective symptomatic responses, positioning these individuals at an 
increased risk for severe hypoglycemia.37
The analysis has several limitations. Self-organizing maps are difficult to validate. The SOM 
analysis was repeated to check for consistency, and resulting clusters were assessed for 
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stability and validity against other clustering algorithms on the raw data. Clusters showed 
stability in cross-validation studies with preservation of patterns in dysglycemia 
(Supplementary Table S3, Supplementary Figure S4). The results may be affected by the 
selection of the CGM metrics used to train the SOM. We explored dysglycemia clustering 
derived from a set of 16- and 24- CGM metrics and found that the recommended number of 
clusters and clustering solutions were not significantly impacted by additional CGM metrics, 
although the projection quality of the SOM was reduced (Supplementary Table S4). In 
addition, the SOM clusters were compared to clusters derived directly from the data.25 
Although the assumptions of the hierarchical clustering algorithm are not met using the 
input data, we found similar clusters with both algorithms (Supplementary Figure S5, 
Supplementary Figure S6). Together, the results suggest that the SOM clusters demonstrate 
internal validity, stability, and accurately represented clustering structure present in the raw 
data.
Additional limitations include availability of CGM data spanning 7 days versus the 14 days 
recommended for optimal data analysis;10 7 days of data may not be representative of long-
term deglycation. The small sample size may be underpowered to detect differences between 
clusters. The inclusion and exclusion criteria of the FLEX trial limit generalizability, 
particularly for adolescents with lower HbA1c levels. In the present analysis, we constrained 
CGM metrics to be consistent with standardized practices of CGM reporting.10 However, 
additional measures of glycemic variability such as mean amplitude of glycemic excursion 
(MAGE) and mean of daily differences (MODD) might help to further delineate subgroups. 
Future work may also explore how deep learning can be used to extract hidden layers of the 
CGM data and explore clusters based on those hidden layers.38
Despite the aforementioned limitations, here, we elucidated dysglycemia phenotypes among 
a sample of adolescents with type 1 diabetes and suboptimal glycemic control, a population 
with great need for future interventions in which CGM data has only recently become 
available to help.8,13 CGM metrics were selected to be consistent with best research 
practices,10 and a clustering algorithm was selected to leverage information from the tails of 
the distribution to understand underlying cluster structure in the data.12 The analytic 
approach is distinct from but compliments ongoing work to model CGM data via temporal 
analysis with regards to the shape of the curve/aspects of glycemic variability,39,40 and it 
may be applied to CGM data from variable durations of wear-time. In full, the study 
represents a novel use of CGM data towards broadening the concept of glycemic control 
from HbA1c to understanding a multifaceted profile that includes glycemic excursions and 
overall variability. Understanding of these subgroups is crucial to pave the way for targeted 
interventions to optimize dysglycemia and the associated clinical outcomes in type 1 
diabetes.
In conclusion, among adolescents with type 1 diabetes and elevated HbA1c, CGM data may 
be pooled and analyzed to uncover subgroups displaying distinct dysglycemia phenotypes, 
for which glycemic control is challenged by different patterns in hypoglycemia, 
hyperglycemia, and glycemic variability. More work is needed to understand the risk factors 
for glycemic control as it is represented from CGM data by dysglycemia phenotypes for 
future development of phenotype-specific interventions to improve glycemic control.
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Figure 1: Use of a Self-Organizing Map (SOM) trained by 7-day continuous glucose monitoring 
(CGM) data to identify Dysglycemia Clusters at baseline of the FLEX trial (n=234).
The clustering is carried out using a two-level approach, where the dataset is first clustered 
onto the units SOM and then the units SOM is clustered. A 5×5 SOM with 25 map units and 
a 3-cluster solution were selected. All CGM-variables were calculated for the 7-day wear 
time and were stratified by day (6:00 AM – 11:59 PM) and night (12:00 AM – 5:59 AM). 
Panel A: Radar plots showing the integrated CGM profile of each of the 25 units on the 
5×5 SOM, as determined by the individuals assigned to that region. Each input CGM 
variable is represented by a different color in the radar. Input CGM variables were defined as 
follows: Hypoglycemia Exposure: area-over-the-curve of 3.9 mmol/L (70 mg/dL), 
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Hypoglycemia Incidence: average number of hypoglycemic (<3.9 mmol/L (70 mg/dL)) 
episodes lasting 15 or more minutes, Hyperglycemia Exposure: area-under-the-curve of 13.9 
mmol/L (250 mg/dL), and Glycemic Variability: %CV. Panel B: The SOM colored by 
Dysglycemia Cluster assignments. Each unit was assigned to a Dyslgycemia Cluster. 
Dysglycemia Cluster assignments (Cluster 1, Cluster 2, and Cluster 3) are shown by colored 
boxes. Panel C: CGM measures of hypoglycemia, hyperglycemia, and glycemic 
variability across the 3 Dysglycemia Clusters. To aid in clinical interpretation of 
hypoglycemia and hyperglycemia exposure, the percent of time are depicted in place of the 
area-over-the-curve and area-under-the-curve measures that were used to construct the SOM. 
Data represents 7-days of blinded CGM wear. All p<0.001. Hypoglycemia Exposure is 
depicted as percent of time <3.9 mmol/L (70 mg/dL). Hypoglycemia Incidence is depicted 
as average number of hypoglycemic (<3.9 mmol/L (70 mg/dL)) episodes lasting 15 or more 
minutes. Hyperglycemia Exposure is depicted as percent of time >13.9 mmol/L (250 mg/
dL). Glycemic Variability is depicted as %CV. Abbreviations: CV – coefficient of variation.
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Figure 2: Longitudinal Hemoglobin A1c (HbA1c) outcomes of FLEX Participants by 
Dysglycemia Cluster, adjusted for FLEX study site and randomization assignment (p-for-
interaction = 0.006).
The p-for-interaction represents Type 3 Test of Fixed Effects for time point × cluster 
interaction term. Missing data— Baseline: n=0; 3-month HbA1c: n= 10; 6-month HbA1c: 
n= 14; 12-month HbA1c: n=20; 18-month HbA1c: n=16. p-values for each 
cluster*timepoint estimate (Cluster 1 vs Cluster 2, Cluster 1 vs Cluster 3): Baseline (p=0.89, 
p<0.0001); 3-month (p=0.23, p=0.08); 6-month (p=0.49, p=0.14), 18-month (p=0.03, 
p=0.85). Abbreviations: HbA1c – hemoglobin A1c.
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